Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia

Leukemia

Volumn 10, Issue 6, 1996, Pages 937-942

  List, A F ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

CD34; Leukemia; Multidrug; Pgp

Indexed keywords

9,10!DIHYDRO 5 METHOXY 9 OXO N [4 [2 (1,2,3,4 TETRAHYDRO 6,7 DIMETHOXY 2 ISOQUINOLINYL)ETHYL]PHENYL] 4 ACRIDINECARBOXAMIDE; AMIDE; ANTHRACYCLINE; CD34 ANTIGEN; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DEXNIGULDIPINE; ELACRIDAR; ETOPOSIDE; GLYCOPROTEIN P; MITOXANTRONE; QUININE; TAMOXIFEN; TIOGUANINE; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL DERIVATIVE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; CLINICAL TRIAL; DRUG TRANSPORT; GENE EXPRESSION; HUMAN; IMMUNOPHENOTYPING; INTRAVENOUS DRUG ADMINISTRATION; KARYOTYPE; METASTASIS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; TREATMENT FAILURE;

EID: 0030058445     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (43)

1. List AF. Multidrug resistance: clinical relevance in acute leukemia (Review). Oncology 1993; 7: 23-32.
2. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Haveloc L, Ludwig H, Lechner K. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991; 83: 708-712.
3. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Magaud JP, Guyotat D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091-3096.
4. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85-94.
5. te Boekhorst PA, de Leeuw K, Schoester M, Wittehol S, Nooter K, Lowenberg B, Sonneveld P. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. Blood 1993; 82: 3157-3162.
6. Samdani A, Glinsmann-Gibson BJ, Grimm MA, Vijapurkar U, Spier CS, Grogan TM, List AF. Cytogenetics and P-glycoprotein are independent predictors of treatment outcome in acute myeloid leukemia (AML). Exp Hematol 1994; 22: 761a.
7. Paietta E, Andersen J, Racevskis J, Gallagher R, Bennett J, Yunis J, Wiernik PH. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia 1994; 8: 968-973.
8. Musto P, Melillo L, Lombardi G, Matera R, di Giorgio G, Carotenuto M. High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br J Haematol 1991; 77: 50-53.
9. te Boekhorst PAW, Lowenberg B, van Kapel J, Nooter K, Sonneveld P. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. Leukemia 1995; 9: 1025-1031.
10. Paietta E, Andersen J, Yunis J, Rowe JM, Cassileth PA. Expression of the multidrug-resistance gene product, P-glycoprotein (PGP), in adult acute myeloid leukemia (AML): association with stem cell factor CD34 and specific cytogenetic abnormalities. Acta Haematologica: 9th Symposium Molecular Biology of Hematopoiesis 1995; 93: 261 (abstr.).
11. Leith CP, Kopecky KJ, Chen I-M, Godwin JE, Appelbaum FR, Head DR, Willman CL. Multidrug resistance (MDR1) expression and function in acute myeloid leukemia (AML) in the elderly: MDR1 and secondary AML status are independent predictors of complete remission (CR). Leukemia 1995; 9: 535 (abstr.).
12. Bailly J-D, Muller C, Jaffrezou J-P, Demur C, Cassar G, Bordier C, Laurent G. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia 1995; 9: 799-807.
13. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor CW, Miller TP, Salmon SE. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989; 7: 415-424.
14. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991; 9: 17-24.
15. Pirker R, Zochbauer S, Kupper H, Lassmann A, Gsur A, Frass M, Knobl P, Lechner K. Dexverapamil as resistance modifier in acute myeloid leukemia. Leukemia 1995; 9: 539 (abstr.).
16. Solary E, Caillot D, Chauffert B, Casasnovas RO, Dumas M, Maynadie M. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 1992; 10: 1730-1736.
17. List AF, Greer JP, Cousar JC, Stein RS, Johnson DH, Reynolds VH, Flexner JM, Hande KR. Non-Hodgkin's lymphoma of the gastrointestinal tract: an analysis of clinical and pathologic features affecting outcome. J Clin Incol 1988; 6: 1125-1133.
18. Marie JP, Bastie JN, Coloma F, Faussat Suberville AM, Delmer A, Rio B, Delmas-Marsalet B, Leroux G, Casassus P, Baumelou E, Catalin J, Zittoun R. Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL). Leukemia 1993; 7: 821-824.
19. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P. In vivo circumvention of P-glycoprotein-mediated multi-drug resistance of tumor cells with SDZ PSC 833. Cancer Res 1991; 51: 4226-4233.
20. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993; 53: 4595-4602.
21. Solary E, Witz B, Caillot D, Moreau P, Desablens B, Cahn JY, Maloisel F, Sadoun A, Pignon B, Guyotat D, Cassassus P, Ifrah N, Audhuy B, Berthou C, Delain M, Lamy T, Harousseau JI. Prospective multicentric randomized study of quinine as a potential MDR-reversing agent for the treatment of acute leukemias. Blood 1995; 86 (Suppl. 1): 780a (abstr.).
22. Ross DD, Wooten PJ, Sridhara R, Ordonez JV, Lee EJ, Schiffer CA. Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 1993; 82: 1288-1299.
23. Marie JP, Faussat-Suberville AM, Zhou D, Zittoun R. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia 1993; 7: 825-831.
24. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC. Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line (see comments). Science 1992; 258: 1650-1654.
25. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML, de Vries EG, van der Valk P, Keijer CJLM, Pinedo HM. Overexpression of a M(r) 110 000 vesicular protein in non-P-glycoprotein-mediated multi-drug resistance. Cancer Res 1993; 53: 1475-1479.
26. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJLM, Clevers HC, Scheper RJ. The drug resistance related protein LRP is a major vault protein. Nat Med 1995; 1: 578-582.
27. Slovak ML, Ho JP, Bhardwaj G, Kurz EU, Deeley RG, Cole SPC. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res 1993; 53: 3221-3225.
28. Krishnamachary N, Center MS. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res 1993; 53: 3658-3661.
29. Eijdems EW, De Haas M, Coco-Martin JM, Ottenheim CP, Zaman GJ, Breuning MH, Twentyman PR, Borst P, Baas F. Mechanisms of MRP over-expression in four human lung-cancer cell lines and analysis of the MRP amplicon. Int J Cancer 1995; 60: 676-684.
30. Abbaszadegan MR, Futscher BW, Klimecki WT, List A, Dalton WS. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res 1994; 54: 4676-4679.
31. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Kaufmann SH. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 1995; 85: 186-193.
32. Burger H, Nooter K, Zaman GJR, Sonneveld P, van Wingerden KE, Oostrum RG, Stoter C. Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia 1994; 8: 990-997.
33. Burger H, Nooter K, Sonneveld P, van Wingerden KE, Zaman GJ, Stoter G. High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia. Br J Haematol 1994; 88: 348-356.
34. Hart SM, Ganeshaguru K, Hoffbrand AV, Prentice HG, Mehta AB. Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia. Leukemia 1994; 8: 2163-2168.
35. Kuss BJ, Deeley RG, Cole SP, Willman CL, Kopecky KJ, Wolman SR, Eyre HJ, Lane SA, Nancarrow JK, Whitmore SA, Callen DF. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. Lancet 1994; 343: 1531-1534.
36. Zhou DC, Zittoun R, Marie JP. Expression of multidrug resistance-associated protein (MRP) gene in acute myeloid leukamia and correlation with expression of multidrug resistance (MDR1) gene. Leukemia 1995; 9: 535 (abstr.).
37. Hipfner DR, Gauldie SD, Deeley RG, Cole SP. Detection of the M(r) 190000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res 1994; 54: 5788-5792.
38. Futscher BW, Abbaszadegan MR, Domann F, Dalton WS. Analysis of MRP mRNA in mitoxantrone-selected, multidrug-resistant human tumor cells. Biochem Pharm 1994; 47: 1601-1606.
39. Vasu SK, Kedersha NL, Rome LH. cDNA cloning and disruption of the major vault protein alpha gene (mvpA) in Dictyostelium discoideum. J Biol Chem 1993; 268: 15356-15360.
40. Rome L, Kedersha N, Chugani D. Unlocking vaults: organalles in search of a function. Trends Cell Biol 1991; 1: 47-50.
41. Dietel M, Arps H, Lage H, Niendorf A. Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257. Cancer Res 1990; 50: 6100-6106.
42. Schuurhuis GJ, Broxterman HJ, de Lange JHM, Pinedo HM, van Heijningen THM, Kuiper CM, Scheffer GL, Scheper RJ, van Kalken CK, Baak JPA, Lankelma J. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br J Cancer 1991; 64: 857-861.
43. List AF, Spier CS, Abbasazdegan M, Grogan TM, Greer JP, Wolff SN, Scheper RJ, Dalton WS. Non-P-glycoprotein (Pgp) mediated multidrug resistance (MDR): identification of a novel drug resistance phenotype with prognostic relevance in acute myeloid leukemia (AML). Blood 1993; 82 (Suppl. 1): 443a.